

Title (en)

ANTI-TGF-BETA ANTIBODIES AND THEIR USE

Title (de)

ANTI-TNF-BETA-ANTIKÖRPER UND DEREN VERWENDUNGEN

Title (fr)

ANTICORPS ANTI-TGF-BÊTA ET LEUR UTILISATION

Publication

**EP 3571227 A1 20191127 (EN)**

Application

**EP 18711394 A 20180119**

Priority

- EP 17305061 A 20170120
- IB 2018000088 W 20180119

Abstract (en)

[origin: WO2018134681A1] The invention provides an improved pan-TGF- $\beta$  antibody for treatment of conditions that are mediated by TGF- $\beta$ , including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

IPC 8 full level

**C07K 16/22** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EA EP US)

**A61P 35/00** (2017.12 - EA EP US); **C07K 16/22** (2013.01 - EA EP US); **C07K 16/2818** (2013.01 - EA EP US); **C07K 16/30** (2013.01 - EA US); **A61K 2039/505** (2013.01 - EA EP US); **A61K 2039/507** (2013.01 - EA EP US); **C07K 2317/52** (2013.01 - EA US); **C07K 2317/56** (2013.01 - EA US); **C07K 2317/565** (2013.01 - EA US); **C07K 2317/76** (2013.01 - EA US); **C07K 2317/92** (2013.01 - EA EP US)

Citation (search report)

See references of WO 2018134681A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**WO 2018134681 A1 20180726**; **WO 2018134681 A8 20190815**; **WO 2018134681 A8 20191010**; EA 201991729 A1 20191230; EP 3571227 A1 20191127

DOCDB simple family (application)

**IB 2018000088 W 20180119**; EA 201991729 A 20180119; EP 18711394 A 20180119